Most Favored Nation (MFN) Model
Conducted rapid analysis of Medicare rulemaking on the Most Favored Nation model introduced by CMMI.
Conducted rapid analysis of Medicare rulemaking on the Most Favored Nation model introduced by CMMI. Assessed methodology, drugs impacted, and provider perspective. Modeled drug-specific impact per administration and annually over the model’s 4 year transition period using ADVI Strategic Analytics and Value Economics (SAVE), and modeled the specialty-level impact for providers based on historical billing. Developed and led market access and field reimbursement training, including key messages and FAQs for field teams.
CEO insights
Related articles
Real analysis from people who’ve been there
Evaluation of Biosimilar Utilization by Hospital Types
Worked with a pharmaceutical trade organization to identify biosimilars of interest.
Advocacy Coalition for Uptake of Comprehensive Genomic Profiling
Worked with a diverse group of industry stakeholders including diagnostics manufacturers, laboratories, academic institutions, and disease-specific advocacy groups to redefine comprehensive genomic profiling through the creation of a “new narrative”.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.